Zoetis Inc. logo ZTS - Zoetis Inc.

Price: -- -- | CONSENSUS: Hold DETAILS
STRONG
BUY 1
BUY 14
HOLD 17
SELL 0
STRONG
SELL 0
| PRICE TARGET: $87.33 DETAILS
HIGH: $95.00
LOW: $80.00
MEDIAN: $85.00
CONSENSUS: $87.33
UPSIDE: 16.32%

Stock News

Zoetis Appoints Iris Knobloch to its Board of Directors

Zoetis Appoints Iris Knobloch to its Board of Directors

PARSIPPANY, N.J.--(BUSINESS WIRE)---- $ZTS #animalhealth--Zoetis Inc. (NYSE:ZTS) today announced the appointment of Iris Knobloch to its Board of Directors, effective as of December 1, 2026. With decades of experience across global media and consumer businesses, Ms. Knobloch brings a distinct combination of international leadership, proven public company board experience across financial services, hospitality and media, and deep consumer and digital expertise to the Zoetis Board. She currently serves on the boards of.

Oct 13, 2026 03:30 AM • businesswire.com
Top 50 High-Quality Dividend Growth Stocks For October 2026

Top 50 High-Quality Dividend Growth Stocks For October 2026

I track an investable universe of 50 high-quality dividend growth stocks to identify attractive entry points based on valuation and future return potential. Applied Materials, D.R. Horton, and Home Depot saw notable ranking improvements due to upgraded EPS growth estimates and/or favorable valuation shifts. 44 out of 50 stocks currently offer a forward return estimate of at least 10%, with 32 appearing potentially undervalued based on free cash flow mean reversion.

Oct 11, 2026 08:46 AM • seekingalpha.com
Zoetis Declares Fourth Quarter 2026 Dividend

Zoetis Declares Fourth Quarter 2026 Dividend

PARSIPPANY, N.J.--(BUSINESS WIRE)---- $ZTS #animalhealth--The Board of Directors of Zoetis Inc. (NYSE:ZTS) has declared a dividend of $0.53 per share for the fourth quarter of 2026. The dividend will be paid on Tuesday, December 1, 2026, to all holders of record of the Company's common stock as of the close of business on Friday, October 30, 2026. About Zoetis Zoetis is the world's leading animal health company, driven by a singular purpose: to nurture our world and humankind by advancing care for animals. With a leg.

Oct 08, 2026 12:15 PM • businesswire.com
New Peer-Reviewed Publication on Laboratory Study That Demonstrated Simparica Trio® Protected 3x More Dogs From Infection With a Resistant Heartworm Isolate Than NexGard® Plus1

New Peer-Reviewed Publication on Laboratory Study That Demonstrated Simparica Trio® Protected 3x More Dogs From Infection With a Resistant Heartworm Isolate Than NexGard® Plus1

PARSIPPANY, N.J.--(BUSINESS WIRE)---- $ZTS #animalhealth--Drug-resistant heartworm is a growing concern for veterinarians and pet owners as resistant heartworm populations emerge. New research shows that not all heartworm preventives perform equally against these resistant isolates. Macrocyclic lactone (ML) resistance means some heartworm isolates are less sensitive to the drug class used in today's heartworm disease preventives. As ML resistance continues to challenge heartworm prevention, veterinarians need data th.

Oct 06, 2026 03:30 AM • businesswire.com
Zoetis: Priced For The Worst, Worth Buying

Zoetis: Priced For The Worst, Worth Buying

Zoetis Inc. (ZTS) has fallen 71% from its 2021 peak, now trading at 2017 levels, as pricing power eroded and pet medicine volumes declined. Despite near-term headwinds, Zoetis maintains industry-leading margins and is positioned to weather price wars better than rivals due to its product mix and scale. Patent expiries for Apoquel and Simparica in 2030/2032 are key risks, but a robust pipeline of 12 candidates could offset revenue losses if half succeed.

Sep 30, 2026 02:31 AM • seekingalpha.com
Zoetis to Host Webcast and Conference Call on Third Quarter 2026 Financial Results

Zoetis to Host Webcast and Conference Call on Third Quarter 2026 Financial Results

PARSIPPANY, N.J.--(BUSINESS WIRE)---- $ZTS #animalhealth--Zoetis Inc. (NYSE:ZTS) will host a webcast and conference call at 8:30 a.m. (ET) on Thursday, November 5, 2026. Chief Executive Officer Kristin Peck and Executive Vice President, Chief Financial Officer and Chief Operating Officer Jay Saccaro will review third quarter 2026 financial results and respond to questions from financial analysts. Investors and the public may access the live webcast and corresponding slides by visiting the Zoetis website at https://in.

Sep 24, 2026 03:30 AM • businesswire.com
Zoetis: An Undervalued Compounder Hiding In Plain Sight

Zoetis: An Undervalued Compounder Hiding In Plain Sight

Zoetis is rated a buy, as I see current headwinds as temporary and the stock undervalued based on my DCF valuation. ZTS faces near-term pressure from weaker U.S. companion animal demand, increased competition, and margin compression due to promotions and rebates. Long-term growth is supported by structural pet humanization trends, international expansion, a robust R&D pipeline, and a growing diagnostics segment.

Sep 17, 2026 01:52 AM • seekingalpha.com
Critical Analysis: Zoetis (NYSE:ZTS) and Urogen Pharma (NASDAQ:URGN)

Critical Analysis: Zoetis (NYSE:ZTS) and Urogen Pharma (NASDAQ:URGN)

Zoetis (NYSE: ZTS - Get Free Report) and Urogen Pharma (NASDAQ: URGN - Get Free Report) are both healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, profitability, earnings, institutional ownership, risk, dividends and valuation. Profitability This table compares Zoetis and Urogen Pharma's net

Sep 09, 2026 11:45 PM • defenseworld.net

Price Targets